Italian guidelines show way out of screening muddle
This article was originally published in Clinica
The Italian Health Ministry has been urged to develop national screening programmes for the most common forms of cancer. A report just published by the Italian National Oncology Commission shows that current measures are at best disjointed and wasteful. It contains guidelines on measures for organising cancer prevention and care and has been published within the framework of Italy's 1994-1996 oncology programme (Gazzetta ufficiale, June 1st).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.